Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00072566 · OUTCOME

Median Overall Survival

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer · Source last updated 2015-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Time from first day of treatment to time of death due to any cause, assessed up to 3 years

What was measured

Calculated using the method of Kaplan-Meier.

Groups in this outcome

Treatment (Bevacizumab, Cyclophosphamide)

Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide 50 mg/d on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV cyclophosphamide: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Bevacizumab, Cyclophosphamide)70

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Bevacizumab, Cyclophosphamide)16.9Not reported11.425.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        11.4
        upper Limit
        25.2
        value
        16.9
denoms
  1. counts
    1. group Id
      OG000
      value
      70
    units
    Participants
description
Calculated using the method of Kaplan-Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide 50 mg/d on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV cyclophosphamide: Given PO
    id
    OG000
    title
    Treatment (Bevacizumab, Cyclophosphamide)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Time from first day of treatment to time of death due to any cause, assessed up to 3 years
title
Median Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice